Group	Drug	Dose (mg/kg)
1	No disease	-
2	Vehicle	QD
3	PRN1008	10, QD
4	PRN1008	20, QD
5	PRN1008	40, QD
6	Dex	1, QD
7	Vehicle	BID
8	PRN1008	20 BID




FIG. 1



Serum BUN levels (measure of kidney function)
Mean±SE BUN level (mg/dL)
0
10
20
30
40
50
60
70
80
90
100%
0%
45%
74%
104%
115%
0%
119%
No disease
Vehicle
QD
Vehicle
-
QD
PRN1008
10 mg/kg
QD
PRN1008
20 mg/kg
QD
PRN1008
40 mg/kg
QD
Dex
1 mg/kg
QD
Vehicle
-
BID
PRN1008
20 mg/kg
BID
Treatment Group
n=10/group
* P≤0.05 T-test to Vehicle

FIG. 2



% Incidence of Severe Proteinurea
BID treatment groups
% severe proteinurea
Study day
Vehicle BID
20 mg/kg PRN1008 BID
Urine Protein Scoring Key (mg/dL)
Severe

FIG. 3B



% Incidence of Severe Proteinuria
QD treatment groups
% severe proteinurea
Study day
Vehicle QD
10 mg/kg PRN1008 QD
20 mg/kg PRN1008 QD
40 mg/kg PRN1008 QD
Dex 1 mg/kg QD
No disease

FIG. 3A



Urine Protein Score Over Time
(Scored 0-5)
Urine Protein Scoring Key
Mean±SE Urine Protein Score (Score 0-5)
Study day

FIG. 4



Absolute Kidney Weight (surrogate of tissue inflammation)
n=10/group
* P<0.05 T-test to Vehicle
Mean±SE Absolute Kidney Weight (g)
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
100%
0%
31%
59%
66%
79%
0%
107%
No disease Vehicle QD
Vehicle - QD
PRN1008 10 mg/kg QD
PRN1008 20 mg/kg QD
PRN1008 40 mg/kg QD
Dex 1 mg/kg QD
Vehicle - BID
PRN1008 20 mg/kg BID

FIG. 5



Glomerulus
Crescents
Protein Cast
Interstitial Inflammation
Vasculitis
Mean±SE Score (0-5)
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Vehicle - No Disease
Vehicle - QD
PRN1008 (10 mg/kg) - QD
PRN1008 (20 mg/kg) - QD
PRN1008 (40 mg/kg) - QD
Dex (1 mg/kg) Positive Control - QD
Vehicle (BID)
PRN1008 (20 mg/kg) - BID

FIG. 6




FIG. 7



% IgM inhibition
100
50
0
-10
-9
-8
-7
-6
-5
Rilzabrutinib Log [M]
aCD40+IL21
CpG (ODN2006)
TNP-LPS

FIG. 8A



% IgG inhibition
100
50
0
-10
-9
-8
-7
-6
-5
Rilzabrutinib Log [M]
aCD40+IL21
CpG (ODN2006)
TNP-LPS

FIG. 8B